Clinical Trial

The Efficacy and Safety of Keverprazan for Helicobacter Pylori Eradication

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated January 16, 2025 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study was to compare the efficacy of 14-day eradication of Helicobacter pylori with different doses of Keverprazan combined with Amoxicillin dual therapy and Keverprazan-based bismuth quadruple therapy and compare the adverse reactions, compliance, and factors affecting the efficacy of eradication schemes among different groups.
Trial Details
NCT Number NCT06777732
Lead Sponsor Nanjing First Hospital, Nanjing Medical University
Conditions Helicobacter Pylori Infection
Enrollment 672 participants
Start Date 2025-03
Primary Completion 2025-09 (estimated)
Study Completion 2026-01 (estimated)
Updated on ClinicalTrials.gov 2025-01-16